Dr Nima Kakho

Staff Specialist

MBBS, FACEM, FCICM

 

Nima grew up in Canada, completing her undergraduate training in British Columbia, before moving to Australia to complete her medical training. After fulfilling her Australian College of Emergency Medicine requirements in 2011, Nima completed her College of Intensive Care Medicine Fellowship requirements in early 2015. She is trained in critical care echocardiography, ECMO, paediatric care, and has spent the last year of her training as a Critical Care Fellow at The Austin ICU, the state spinal and liver transplant centre.

NK
Head of Education

Nima is the lead for the ICU education portfolio

Latest news: 
  • Tuesday, June 29, 2021 - 17:07

    NEJM TTM2: hypothermia (33C for 28 hrs then avoid >37.8C to 72 hrs) vs normothermia ( <37.8C), after OHCA + coma = no difference death and poor functional outcome at 6 months. In general TTM1 and 2 report no difference between 33, 36, and 37.8C.

    Saturday, May 29, 2021 - 17:55

    JAMA COBI RCT continuous infusion 20% hypertonic saline vs standard care for minimum 48 hours in moderate to severe TBI =  no difference neurological outcome 6 months. Intervention associated lower risk intracranial hypertension for 1st 2-days, followed by rebound ICH, apparent after cessation of therapy.

    Wednesday, May 12, 2021 - 17:20

    JAMA MIS-C - Observational study of combined treatment with IVIG + methylprednisolone vs IVIG alone associated with reduced treatment failure, new LV dysfunction, hemodynamic support, and PICU LOS better course of fever in children with MIS-C.

    Tuesday, May 11, 2021 - 14:37

    JAMA REALITY - Restrictive transfusion strategy compared with a liberal strategy resulted in a noninferior rate of major cardiovascular events among patients with acute myocardial infarction and anemia.

    Monday, May 10, 2021 - 19:06

    NEJM CONFIRM terlipressin with albumin more effective than albumin alone at reversing hepatorenal syndrome in adults with cirrhosis and HRS-1. Interesting cautionary discussion about terlipressin association with more serious adverse events, particularly respiratory failure..